|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: OGFOD2 |
Gene summary for OGFOD2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | OGFOD2 | Gene ID | 79676 |
| Gene name | 2-oxoglutarate and iron dependent oxygenase domain containing 2 | |
| Gene Alias | OGFOD2 | |
| Cytomap | 12q24.31 | |
| Gene Type | protein-coding | GO ID | GO:0003674 | UniProtAcc | Q6N063 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 79676 | OGFOD2 | LZE4T | Human | Esophagus | ESCC | 8.35e-06 | 1.72e-01 | 0.0811 |
| 79676 | OGFOD2 | LZE7T | Human | Esophagus | ESCC | 6.33e-03 | 1.95e-01 | 0.0667 |
| 79676 | OGFOD2 | LZE8T | Human | Esophagus | ESCC | 2.72e-03 | 1.44e-01 | 0.067 |
| 79676 | OGFOD2 | LZE24T | Human | Esophagus | ESCC | 6.88e-12 | 2.72e-01 | 0.0596 |
| 79676 | OGFOD2 | P1T-E | Human | Esophagus | ESCC | 3.58e-07 | 2.78e-01 | 0.0875 |
| 79676 | OGFOD2 | P2T-E | Human | Esophagus | ESCC | 9.78e-30 | 4.85e-01 | 0.1177 |
| 79676 | OGFOD2 | P4T-E | Human | Esophagus | ESCC | 4.51e-19 | 3.69e-01 | 0.1323 |
| 79676 | OGFOD2 | P5T-E | Human | Esophagus | ESCC | 3.89e-12 | 2.46e-01 | 0.1327 |
| 79676 | OGFOD2 | P8T-E | Human | Esophagus | ESCC | 9.67e-18 | 3.03e-01 | 0.0889 |
| 79676 | OGFOD2 | P9T-E | Human | Esophagus | ESCC | 2.41e-06 | 1.62e-01 | 0.1131 |
| 79676 | OGFOD2 | P10T-E | Human | Esophagus | ESCC | 2.93e-15 | 2.49e-01 | 0.116 |
| 79676 | OGFOD2 | P11T-E | Human | Esophagus | ESCC | 6.27e-12 | 4.15e-01 | 0.1426 |
| 79676 | OGFOD2 | P12T-E | Human | Esophagus | ESCC | 4.12e-11 | 2.33e-01 | 0.1122 |
| 79676 | OGFOD2 | P15T-E | Human | Esophagus | ESCC | 4.01e-11 | 2.42e-01 | 0.1149 |
| 79676 | OGFOD2 | P16T-E | Human | Esophagus | ESCC | 8.56e-12 | 2.56e-01 | 0.1153 |
| 79676 | OGFOD2 | P17T-E | Human | Esophagus | ESCC | 3.52e-10 | 3.87e-01 | 0.1278 |
| 79676 | OGFOD2 | P19T-E | Human | Esophagus | ESCC | 5.57e-05 | 4.05e-01 | 0.1662 |
| 79676 | OGFOD2 | P20T-E | Human | Esophagus | ESCC | 5.63e-18 | 3.52e-01 | 0.1124 |
| 79676 | OGFOD2 | P21T-E | Human | Esophagus | ESCC | 4.05e-32 | 5.54e-01 | 0.1617 |
| 79676 | OGFOD2 | P22T-E | Human | Esophagus | ESCC | 3.28e-14 | 2.61e-01 | 0.1236 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| OGFOD2 | SNV | Missense_Mutation | c.278G>C | p.Arg93Pro | p.R93P | Q6N063 | protein_coding | deleterious(0.02) | possibly_damaging(0.78) | TCGA-A2-A0YM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| OGFOD2 | deletion | Frame_Shift_Del | novel | c.200delN | p.Glu67GlyfsTer46 | p.E67Gfs*46 | Q6N063 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| OGFOD2 | SNV | Missense_Mutation | novel | c.874N>A | p.Ala292Thr | p.A292T | Q6N063 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| OGFOD2 | SNV | Missense_Mutation | rs376678539 | c.763N>A | p.Ala255Thr | p.A255T | Q6N063 | protein_coding | tolerated(0.15) | benign(0.001) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| OGFOD2 | SNV | Missense_Mutation | rs376678539 | c.763G>A | p.Ala255Thr | p.A255T | Q6N063 | protein_coding | tolerated(0.15) | benign(0.001) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| OGFOD2 | SNV | Missense_Mutation | rs771444144 | c.718N>A | p.Glu240Lys | p.E240K | Q6N063 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| OGFOD2 | deletion | Frame_Shift_Del | novel | c.353delN | p.Pro119GlnfsTer55 | p.P119Qfs*55 | Q6N063 | protein_coding | TCGA-AA-3949-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | ||
| OGFOD2 | SNV | Missense_Mutation | rs201145539 | c.1028C>T | p.Thr343Met | p.T343M | Q6N063 | protein_coding | tolerated(0.12) | benign(0.034) | TCGA-A5-A0GB-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| OGFOD2 | SNV | Missense_Mutation | c.250C>A | p.Leu84Ile | p.L84I | Q6N063 | protein_coding | tolerated(0.76) | benign(0.003) | TCGA-A5-A0VP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| OGFOD2 | SNV | Missense_Mutation | novel | c.944G>A | p.Ser315Asn | p.S315N | Q6N063 | protein_coding | tolerated(0.07) | benign(0.007) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |